The prostate cancer drug abiraterone has been provisionally rejected as a first-line treatment on the NHS in England.
By studying small differences in our DNA, called SNPs, our scientists are showing how these could be used to help prevent cancer in the future.
Questions are being asked of the tests used to diagnose prostate cancer, and how they can be improved. We cover the latest research, including specialist MRI.
More than a quarter of men with suspected prostate cancer could avoid invasive biopsies if they’re offered an MRI scan first, a new study suggests.
With new cancer detection technology on the horizon, ranging from blood tests to wristbands, understanding overdiagnosis is a huge challenge.
Our new research shows that a one-off PSA test doesn't save lives from prostate cancer.
Inviting men with no symptoms to a one-off PSA test for prostate cancer does not save lives according to results from the largest ever prostate cancer trial.
An experimental hormone therapy delays the spread of prostate cancer that has stopped responding to standard treatment, according to new clinical trial results.
Analysing big data to predict men’s risk of side effects could help personalise radiotherapy treatment for prostate cancer.
Men with unusually low amounts of testosterone in their blood are around 20% less likely to develop prostate cancer.